SELÇUK KANAT, Ferit Onur MUTLUER

Long-Term Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy

INTRODUCTION: For ablation of ventricular tachycardia (VT) in patients with ischemic cardiomyopathy (ICM), an electroanatomical mapping (3D EAM) system is constantly used. The goal of this study was to determine the long-term outcomes of substrate mapping and catheter ablation (CA) of Ventricular Tachycardia in ICM. METHODS: The study included 41 consecutive patients with ICM. Substrate mapping and ablation were performed to all patients using 3D EAM. Patients were followed up for acute procedure success, periprosedural complications, mortality and recurrence of VT. RESULTS: For patients that included in this study, mean age was 61 ± 7 and majority of the patients was male (38, 92.6 %). Mean follow-up duration was 16.5 ± 8.5 months and in the follow up duration 6 (14,6%) of study patients were lost and 10 (24,3%) experienced VT recurred. Periprocedural complications occurred in 5 of the patients (11.9 %). DISCUSSION AND CONCLUSION: In a single center retrospective study, when using a 3D EAM guided approach for VT ablation in patients with ischemic cardiomyopathy, the freedom from any ventricular arrhythmia has found high (75.6 %). Substrate mapping and ablation during on sinus rhythm or under pacing shown as successful which we demonstrated in our study.

İskemik Ventriküler Taşikardi Katater Ablasyonu Yapılan Hastaların Uzun Dönem Sonuçları

GİRİŞ ve AMAÇ: İskemik kardiyomiyopatili (ICM) hastalarda ventriküler taşikardinin (VT) ablasyonu için sürekli olarak bir elektroanatomik haritalama (3D EAM) sistemi kullanılmaktadır. Bu çalışmanın amacı, ICM'de ventriküler taşikardide substrat haritalama ve kateter ablasyonunun (CA) uzun dönem sonuçlarını belirlemektir. YÖNTEM ve GEREÇLER: Çalışmaya ICM'li 41 ardışık hasta alındı. 3D EAM kullanan tüm hastalara substrat haritalama ve ablasyon uygulandı. Hastalar akut işlem başarısı, periprosedural komplikasyonlar, mortalite ve VT nüksü açısından takip edildi. BULGULAR: Bu çalışmaya dahil edilen hastalar için yaş ortalaması 61 ± 7 ve hastaların çoğu erkekti (38% 92,6). Ortalama takip süresi 16,5 ± 8,5 aydı ve takip süresinde 6 (% 14,6) hasta kaybedildi ve 10 (% 24,3) VT olgusunda nüks görüldü. Periprosedural komplikasyonlar hastaların 5'inde (% 11.9) meydana geldi. TARTIŞMA ve SONUÇ: Tek merkezli bir retrospektif çalışmada, iskemik kardiyomiyopatili hastalarda için,3D EAM destekli bir yaklaşım ile VT ablasyonu uygulandığında,uzun dönem başarısı yüksek bulundu (% 75.6). Çalışmamızda, sinüs ritmi yada ventriküler pacing altında, substrat haritalama ve ablasyon başarısı gösterilmiştir.

PDF

___

1. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–754
2. 2. Sapp JL, Parkash R, Tang AS. Ventricular tachycardia ablation versus antiarrhythmic-drug escalation. N Engl J Med. 2016;375:1499–1500. doi: 10.1056/NEJMc1610234.
3. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2017 Oct 25 [Epub ahead of print].
4. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2015;26:151–7.
5. Kumar S, Romero J, Mehta NK, Fujii A, Kapur S, Baldinger SH, Barbhaiya CR, Koplan BA, John RM, Epstein LM, Michaud GF, Tedrow UB, Stevenson WG. Long-term outcomes after catheter
6. Wolf M, Sacher F, Cochet H, Kitamura T, Takigawa M, Yamashita S, et al. Long-term outcome of substrate modification in ablation of postmyocardial infarction ventricular tachycardia. Circ Arrhythm Electrophysiol 2018;11:e005635.
7. Sosa E, Scanavacca M, d’Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol 1996;7:531–6.
8. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E: Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000;101:1288-1296.
9. Cano O, Hutchinson M, Lin D, Garcia F, Zado E, Bala R, Riley M, Cooper J, Dixit S, Gerstenfeld E, Callans D, Marchlinski FE. Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy. J Am Coll Cardiol 2009;54:799 – 808
10. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995;92:3255–63.
11. Verma A, Kilicaslan F, Marrouche NF, et al. Prevalence, predictors and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol 2004;15:1265– 70.
12. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Multicenter Thermocool VT Ablation Trial Investigators. Circulation 2008;118:2773–82.
13. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol 2000; 35: 1905–14
14. Porta-Sánchez A, Jackson N, Lukac P, et al. Multicenter study of ischemic ventricular tachycardia ablation with decrement evoked potential (DEEP) mapping with extra stimulus. J Am Coll Cardio EP 2018;4:307–15.
15. Lin CY, Chung FP, Lin YJ, et al. Safety and efficacy of epicardial ablation of ventricular tachyarrhythmias: experience from a tertiary referral center in Taiwan. Acta Cardiol Sin 2018;34:49–58
16. Maagh P, Christoph A, Dopp H, et al. Highdensity mapping in ventricular tachycardia ablation: a PentaRay® study. Cardiol Res 2017;8:293–303.
17. Kivanc Yalin, Ebru Golcuk, Ahmet Kaya Bilge, et al. Combined analysis of unipolar and bipolar voltage mapping identifies recurrences after unmappable scar-related ventricular tachycardia ablation. Europace (2015) 17, 1580–1586
18. Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar related ventricular tachycardia. Circulation 2012;125:2184–96.
19. Tung R, Mathuria NS, Nagel R, et al. Impact of local ablation on interconnected channels within ventricular scar: mechanistic implications for substrate modification. Circ Arrhythm Electrophysiol 2013;6:1131–8.
20. Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol 2015;66:2872- 82.
21. Tümer Erdem Guler, Kıvanç Yalin, Tolga Aksu, et al. Prognostic value role of radiofrequency lesion size by cardiac magnetic resonance imaging on outcomes of ablation in patients with ischemic scar-related ventricular tachycardia. Medicine (2018) 97:46
22. Santangeli P.,Frankel D.S., Tung R. et al. (2017) Early mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol 69:2105–2115.
23. Siregar S, Groenwold RH, de Mol BA, et al. Evaluation of cardiac surgery mortality rates: 30-day mortality or longer follow-up? Eur J Cardiothorac Surg 2013;44:875–83.
24. Hannan EL, Racz MJ, Walford G, et al. Longterm outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352:2174–83.
25. Tanner H, Hindricks G, Volkmer M, Furniss S, Kühlkamp V, Lacroix D, DE Chillou C, Almendral J, Caponi D, Kuck KH, Kottkamp H. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-Study.J Cardiovasc Electrophysiol. 2010;21:47–53
26. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, Pitschner HF, Kautzner J, Schumacher B, Hansen PS, group Vs. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31– 40
27. . Delacretaz E, Stevenson WG: Catheter ablation of ventricular tachycardia in patients with coronary heart disease: Part I: Mapping. Pacing Clin Electrophysiol 2001;24:1261-1277.
28. Dinov B, Arya A, Bertagnolli L, Schirripa V, Schoene K, Sommer P, Bollmann A, Rolf S, Hindricks G. Early referral for ablation of scarrelated ventricular tachycardia is associated with improved acute and long-term outcomes: results from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm Electrophysiol 2014;7:1144 –1151.